JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB287038

Apoptozole

Be the first to review this product! Submit a review

|

(0 Publication)

MW 625.6 Da, Purity >98%. Apoptozole is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14 μM, respectively. Apoptozole dose-dependently induces apoptosis in cancer cells (IC₅₀ = 5-7 μM). It prevents the association of Hsp70 with apoptotic protease-activating factor 1 and triggers caspase activation in HeLa cells.

View Alternative Names

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase, Albendazole sulfoxidase, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC9, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIC9, CYPIIIA3, CYPIIIA4, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-PCN1, Glucocorticoid inducible P450, HLP, MGC126680, MGC149605, MGC88320, Microsomal monooxygenase, NF 25, Nifedipine oxidase, OTTHUMP00000020135, P450 III steroid inducible, P450 MP, P450 PB 1, P450 PCN1, P450, family III, P450C3, P450IIC9, Quinine 3-monooxygenase, S-mephenytoin 4-hydroxylase, Taurochenodeoxycholate 6-alpha-hydroxylase, Xenobiotic monooxygenase, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, flavoprotein-linked monooxygenase

Key facts

CAS number

1054543-47-3

Purity

>98%

Form

Solid

form

Molecular weight

625.6 Da

Molecular formula

C<sub>3</sub><sub>3</sub>H<sub>2</sub><sub>5</sub>F<sub>6</sub>N<sub>3</sub>O<sub>3</sub>

PubChem

24894064

Nature

Synthetic

Solubility

Soluble in DMSO to >50 mM

Biochemical name

Apoptozole

Biological description

Apoptozole is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14 μM, respectively. Apoptozole dose-dependently induces apoptosis in cancer cells (IC₅₀ = 5-7 μM). It prevents the association of Hsp70 with apoptotic protease-activating factor 1 and triggers caspase activation in HeLa cells.

Canonical smiles

COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC

InChi

InChI=1S/C33H25F6N3O3/c1-44-26-11-7-20(8-12-26)28-29(21-9-13-27(45-2)14-10-21)42(18-19-3-5-22(6-4-19)30(40)43)31(41-28)23-15-24(32(34,35)36)17-25(16-23)33(37,38)39/h3-17H,18H2,1-2H3,(H2,40,43)

InChiKey

ZIMMTPFXOMAJTQ-UHFFFAOYSA-N

IUPAC Name

4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide

style
left-column

Product details

This product is manufactured by BioVision, an Abcam company and was previously called B2412 Apoptozole. B2412-5 is the same size as the 5 mg size of ab287038.
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome P450 3A4 (CYP3A4) and CYP2C9 are important enzymes involved in drug metabolism. They belong to the cytochrome P450 family with CYP3A4 being the most abundant isoform in the liver. CYP3A4 has a molecular mass of approximately 57 kDa and CYP2C9 has a mass around 55 kDa. Both enzymes are primarily expressed in the liver and intestine. These enzymes play an important role in the oxidation of various endogenous and exogenous compounds including a wide range of pharmaceutical drugs steroids and fatty acids.
Biological function summary

Cytochromes like CYP3A4 and CYP2C9 contribute to the detoxification process in the body. They facilitate the conversion of lipophilic substances into more hydrophilic compounds aiding in their excretion. CYP3A4 and CYP2C9 are part of a large superfamily of enzymes known as the monooxygenases which require NADPH and cytochrome P450 reductase to function efficiently. The presence of these cytochromes in the liver strongly indicates their role in first-pass metabolism where they modify drugs before they enter systemic circulation.

Pathways

CYP3A4 and CYP2C9 are central in the drug metabolism pathway especially those called phase I metabolic pathways. These pathways involve the modification of drugs by oxidation reduction or hydrolysis. CYP3A4 and CYP2C9 assist in the biotransformation of drug molecules often dictating their pharmacokinetic properties. They are closely related to other proteins within these pathways including CYP1A2 and CYP2D6 that metabolize different drug substrates but work concurrently to ensure efficient metabolism.

CYP3A4 and CYP2C9 play a significant role in hepatotoxicity and drug-drug interactions. Alterations in their expression or activity can lead to improper drug metabolism resulting in either drug accumulation or therapeutic failure. Both enzymes are important in conditions like liver cirrhosis where their activity often decreases affecting drug clearance rates. Additionally the enzymes are involved in disorders like genetic polymorphisms which can alter individuals' responses to medication. There is a relation to the protein P-glycoprotein part of the multi-drug resistance family which interacts with CYP enzymes in the process of drug transport and metabolism.
style
left-column
style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Biochemicals

AB120503

BAPTA-AM, Ca2+ chelator

Chemical Structure - BAPTA-AM, Ca2+ chelator (AB120503)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Flow Cytometry - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Biochemicals

AB120914

Xestospongin C, IP3 receptor antagonist

Chemical Structure - Xestospongin C, IP3 receptor antagonist (AB120914)

  • 0
  • 0
Primary Antibodies

AB192890

Anti-LC3B antibody [EPR18709] - Autophagosome Marker

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|Lab Essentials|20ul selling size

Western blot - Anti-LC3B antibody [EPR18709] - Autophagosome Marker (AB192890)

  • 5
  • 19

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com